Cargando…

Brodalumab in the treatment of psoriatic arthritis – the latest reports

Detalles Bibliográficos
Autor principal:	Banaszczyk, Katarzyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103410/ https://www.ncbi.nlm.nih.gov/pubmed/33976468 http://dx.doi.org/10.5114/reum.2021.105455

Ejemplares similares

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
por: Elgaard, Cathrine Dawn Büttner, et al.
Publicado: (2023)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis
por: Barbarroja, Nuria, et al.
Publicado: (2019)

Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab
por: Megna, Matteo, et al.
Publicado: (2022)

Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis
por: Kokolakis, Georgios, et al.
Publicado: (2022)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis
por: Corrado, Addolorata, et al.
Publicado: (2017)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Three‐year U.S. pharmacovigilance report of brodalumab
por: Lebwohl, Mark, et al.
Publicado: (2021)

Two-Year US Pharmacovigilance Report on Brodalumab
por: Lebwohl, Mark, et al.
Publicado: (2020)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

A comparison of disease impact according to the cardiometabolic risk profile in psoriatic arthritis
por: Queiro, Rubén, et al.
Publicado: (2021)

Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy
por: Yamada, Saori, et al.
Publicado: (2016)

Psoriatic Arthritis Complicating Systemic Sclerosis: Possible Involvement of M2 Macrophages
por: Yamaoka, Toshifumi, et al.
Publicado: (2015)

A sarcoidosis patient developing psoriatic arthritis 18 years later: First description
por: de Carvalho, Jozélio Freire
Publicado: (2023)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Psychobiotics: The Latest Psychotropics
por: Gnanavel, Sundar
Publicado: (2015)

Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
por: Valor-Méndez, Larissa, et al.
Publicado: (2022)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Leave pooling—the latest trend: Implications
por: Upadhyaya, Suneet Kumar, et al.
Publicado: (2011)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Rapid resolution of pyoderma gangrenosum with brodalumab therapy
por: Tee, Michael W., et al.
Publicado: (2020)

Pharmacogenetics of Treatment Response in Psoriatic Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

The benefits of combining the latest technology in thoracic surgery
por: Gooseman, Michael R., et al.
Publicado: (2023)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention
por: Zabotti, Alen, et al.
Publicado: (2020)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

Self-plagiarism: The Latest Ethical Dilemma in Biomedical Research
por: Gnanavel, Sundar
Publicado: (2014)

Complexities in Genetics of Psoriatic Arthritis
por: Rahmati, Sara, et al.
Publicado: (2020)

First Reported Mycobacterium Marinum Infection Case in a Patient With Psoriatic Arthritis Maintained on Golimumab
por: RIDA, Mohamad Ali, et al.
Publicado: (2020)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
por: Coimbra, Susana, et al.
Publicado: (2014)

Treatment recommendations for psoriatic arthritis
por: Ritchlin, C T, et al.
Publicado: (2009)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis
por: Buononato, Dario, et al.
Publicado: (2022)

Enthesitis in Psoriatic Arthritis, the Sonographic Perspective
por: Smerilli, Gianluca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5rpa45jh80d201gc75i0en6pii